Global incidence and mortality of renal cell carcinoma in 2020.
10.3760/cma.j.cn112338-20220624-00558
- Author:
Ming HU
1
;
Jun Yan FAN
1
;
Xiong ZHOU
1
;
Guang Wen CAO
1
;
Xiaojie TAN
1
Author Information
1. Department of Epidemiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
- Publication Type:Journal Article
- MeSH:
Male;
Humans;
Female;
Adult;
Middle Aged;
Infant, Newborn;
Infant;
Child, Preschool;
Child;
Adolescent;
Young Adult;
Aged;
Carcinoma, Renal Cell/epidemiology*;
Incidence;
Databases, Factual;
China;
Kidney Neoplasms/epidemiology*;
Global Health
- From:
Chinese Journal of Epidemiology
2023;44(4):575-580
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the global epidemiology of renal cell carcinoma (RCC) in 2020. Methods: The incidence and mortality data of RCC in the cooperative database GLOBOCAN 2020 of International Agency for Research on Cancer of WHO and the human development index (HDI) published by the United Nations Development Programme in 2020 were collated. The crude incidence rate (CIR), age-standardized incidence rate (ASIR), crude mortality rate (CMR), age-standardized mortality rate (ASMR) and mortality/incidence ratio (M/I) of RCC were calculated. Kruskale-Wallis test was used to analyze the differences in ASIR or ASMR among HDI countries. Results: In 2020, the global ASIR of RCC was 4.6/100 000, of which 6.1/100 000 for males and 3.2/100 000 for females and ASIR was higher in very high and high HDI countries than that in medium and low HDI countries. With the rapid increase of age after the age of 20, the growth rate of ASIR in males was faster than that in females, and slowed down at the age of 70 to 75. The truncation incidence rate of 35-64 years old was 7.5/100 000 and the cumulative incidence risk of 0-74 years old was 0.52%. The global ASMR of RCC was 1.8/100 000, 2.5/100 000 for males and 1.2/100 000 for females. The ASMR of males in very high and high HDI countries (2.4/100 000-3.7/100 000) was about twice that of males (1.1/100 000-1.4/100 000) in medium and low HDI countries, while the ASMR of female (0.6/100 000-1.5/100 000) did not show significant difference. ASMR continued to increase rapidly with age after the age of 40, and the growth rate of males was faster than that of females. The truncation mortality rate of 35-64 years old was 2.1/100 000, and the cumulative mortality risk of 0-74 years old was 0.20%. M/I decreases with the increase of HDI, with M/I as 0.58 in China, which was higher than the global average of 0.39 and the United States' 0.17. Conclusion: The ASIR and ASMR of RCC presented significant regional and gender disparities globally, and the heaviest burden was in very high HDI countries.
